Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Attribution of 12 High-Risk Human Papillomavirus Genotypes to Infection and Cervical Disease
Elmar A. Joura, Kevin A. Ault, F. Xavier Bosch, et al.
Cancer Epidemiology Biomarkers & Prevention (2014) Vol. 23, Iss. 10, pp. 1997-2008
Open Access | Times Cited: 168

Showing 1-25 of 168 citing articles:

A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women
Elmar A. Joura, Anna R. Giuliano, Ole‐Erik Iversen, et al.
New England Journal of Medicine (2015) Vol. 372, Iss. 8, pp. 711-723
Open Access | Times Cited: 1230
Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience
Suzanne M. Garland, Susanne K. Kjær, Nubia Muñóz, et al.
Clinical Infectious Diseases (2016) Vol. 63, Iss. 4, pp. 519-527
Open Access | Times Cited: 436
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial
Warner K. Huh, Elmar A. Joura, Anna R. Giuliano, et al.
The Lancet (2017) Vol. 390, Iss. 10108, pp. 2143-2159
Open Access | Times Cited: 401
Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women
Ole‐Erik Iversen, María J. Miranda, Àngels Ulied, et al.
JAMA (2016) Vol. 316, Iss. 22, pp. 2411-2411
Closed Access | Times Cited: 174
Parental acceptance and uptake of the HPV vaccine among African-Americans and Latinos in the United States: A literature review
Kayoll V. Galbraith, Julia Lechuga, Coretta Jenerette, et al.
Social Science & Medicine (2016) Vol. 159, pp. 116-126
Closed Access | Times Cited: 113
Diseases of the tongue
Aaron R. Mangold, Rochelle R. Torgerson, Roy S. Rogers
Clinics in Dermatology (2016) Vol. 34, Iss. 4, pp. 458-469
Closed Access | Times Cited: 104
Introduction of molecular HPV testing as the primary technology in cervical cancer screening: Acting on evidence to change the current paradigm
Joseph E. Tota, J. Bentley, Jennifer Blake, et al.
Preventive Medicine (2017) Vol. 98, pp. 5-14
Closed Access | Times Cited: 104
A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9–15-Year-Old Girls
Timo Vesikari, Nicholas Brodszki, Pierre Van Damme, et al.
The Pediatric Infectious Disease Journal (2015) Vol. 34, Iss. 9, pp. 992-998
Open Access | Times Cited: 98
Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population
Anna R. Giuliano, Elmar A. Joura, Suzanne M. Garland, et al.
Gynecologic Oncology (2019) Vol. 154, Iss. 1, pp. 110-117
Open Access | Times Cited: 80
Screening for Cervical Cancer
Terresa J. Eun, Rebecca B. Perkins
Medical Clinics of North America (2020) Vol. 104, Iss. 6, pp. 1063-1078
Open Access | Times Cited: 71
High rate of non-vaccine targeted high-risk HPV genotypes circulate among women in Eastern Ethiopia
Ayichew Seyoum, Berhanu Seyoum, Tadesse Gure, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 10
Estimation of the epidemiological burden of HPV-related anogenital cancers, precancerous lesions, and genital warts in women and men in Europe: Potential additional benefit of a nine-valent second generation HPV vaccine compared to first generation HPV vaccines
Susanne Hartwig, Jean‐Jacques Baldauf, Géraldine Dominiak-Felden, et al.
Papillomavirus Research (2015) Vol. 1, pp. 90-100
Open Access | Times Cited: 88
From the monovalent to the nine-valent HPV vaccine
Sophie Pils, Elmar A. Joura
Clinical Microbiology and Infection (2015) Vol. 21, Iss. 9, pp. 827-833
Open Access | Times Cited: 74
Molecular tests potentially improving HPV screening and genotyping for cervical cancer prevention
Ana Gradíssimo, Robert D. Burk
Expert Review of Molecular Diagnostics (2017) Vol. 17, Iss. 4, pp. 379-391
Open Access | Times Cited: 71
Developments in L2-based human papillomavirus (HPV) vaccines
Christina Schellenbacher, Richard B.S. Roden, Reinhard Kirnbauer
Virus Research (2016) Vol. 231, pp. 166-175
Open Access | Times Cited: 70
Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence
Carlo Signorelli, Anna Odone, Veronica Ciorba, et al.
Epidemiology and Infection (2017) Vol. 145, Iss. 10, pp. 1962-1982
Open Access | Times Cited: 69
Need for expanded HPV genotyping for cervical screening
Jack Cuzick, Cosette M. Wheeler
Papillomavirus Research (2016) Vol. 2, pp. 112-115
Open Access | Times Cited: 65
The Complex Interplay between Vaginal Microbiota, HPV Infection, and Immunological Microenvironment in Cervical Intraepithelial Neoplasia: A Literature Review
Bárbara Gardella, Marianna Francesca Pasquali, Marco La Verde, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 13, pp. 7174-7174
Open Access | Times Cited: 32
Distribution of human papillomavirus genotypes by severity of cervical lesions in HPV screened positive women from the ESTAMPA study in Latin America
Rita Mariel Correa, Armando Baena, Joan Valls, et al.
PLoS ONE (2022) Vol. 17, Iss. 7, pp. e0272205-e0272205
Open Access | Times Cited: 31
Looking beyond human papillomavirus (HPV) genotype 16 and 18: Defining HPV genotype distribution in cervical cancers in Australia prior to vaccination
Julia Brotherton, Sepehr N. Tabrizi, Samuel Phillips, et al.
International Journal of Cancer (2017) Vol. 141, Iss. 8, pp. 1576-1584
Open Access | Times Cited: 62
Ten years of HPV vaccines: State of art and controversies
Roberto Angioli, Salvatore Lopez, Alessia Aloisi, et al.
Critical Reviews in Oncology/Hematology (2016) Vol. 102, pp. 65-72
Closed Access | Times Cited: 58
AACR Cancer Progress Report 2015
José Baselga, Nina Bhardwaj, Lewis C. Cantley, et al.
Clinical Cancer Research (2015) Vol. 21, Iss. 19_Supplement, pp. S1-S128
Open Access | Times Cited: 54
9-Valent human papillomavirus vaccine: a review of the clinical development program
Alain Luxembourg, Erin Moeller
Expert Review of Vaccines (2017) Vol. 16, Iss. 11, pp. 1119-1139
Closed Access | Times Cited: 54
A 9-Valent HPV Vaccine Against Infection and Intraepithelial Neoplasia in Women
Elmar A. Joura, Anna R. Giuliano, Ole‐Erik Iversen, et al.
Obstetrical & Gynecological Survey (2015) Vol. 70, Iss. 7, pp. 446-448
Open Access | Times Cited: 51
Prevalence of high-risk HPV genotypes, categorised by their quadrivalent and nine-valent HPV vaccination coverage, and the genotype association with high-grade lesions
María Paz‐Zulueta, Ledicia Álvarez-Paredes, Juan Carlos Rodrı́guez, et al.
BMC Cancer (2018) Vol. 18, Iss. 1
Open Access | Times Cited: 48
Page 1 - Next Page

Scroll to top